New Products

RIVERDALE, N.Y. — Consumers can now banish unsightly tan lines thanks to the tan line corrector from Tanee.

This marks the first time that a company has addressed the tan line as an aspect of sun care, the company stated. The product won the DSN/ECRM Best New Product award during the recent ECRM Sun Care event.

NORTH LIMA, Ohio — Perfecta Products on Wednesday announced expansion of its Zim's Maximum Heat external analgesic.

Maximum Heat is indicated for the temporary relief of muscle, back, shoulder and neck pain. It is the sister product of Perfecta's Zim's Max-Freeze. Zim's Maximum Heat is formulated with aloe, arnica, vitamin E and tea tree oil.

Both the 2.5-oz. Zim's Maximum Heat Roll-On and 3.5-oz. tube of Zim's Maximum Heat retail for a suggested $10.49.

WHITE PLAINS, N.Y. – Sabra Dipping Co., the country's leading hummus manufacturer, has introduced a new flavor of its Garden Variety Hummus — Asian Fusion.

Inspired by Asian cuisine, the new flavor of hummus incorporates the flavors of ginger and sesame, and is topped with crunchy carrots and peppers.

PALATINE, Ill. — Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine. Couched as the "next generation pseudoephedrine product," Nexafed is a 30-mg PSE hydrochloride tablet that utilizes Acura's trademarked Impede technology. 

PARSIPPANY, N.J. – The Food and Drug Administration has approved a Type 2 diabetes drug made by Watson Pharmaceuticals, the company said, following a federal court's order for the agency to approve the drug.

Watson announced the launch of pioglitazone hydrochloride tablets in the 15-mg, 30-mg and 45-mg strengths. The drug is a generic version of Takeda's Actos, branded and generic versions of which had sales of about $2.7 billion during the 12-month period ended in August, according to IMS Health.

MOUNT PROSPECT, Ill. — About 97% of online pharmacies are "rogue" operations operating outside U.S. laws and regulations, according to a new report.

SILVER SPRING, Md. — The Food and Drug Administration has approved what it called the second new drug in two months for a form of leukemia, the agency said Friday.

The FDA announced the approval of Teva Pharmaceutical Industries' Synribo (omacetaxine mepesuccinate) for chronic myelogenous leukemia, or CML, a disease that the National Institutes of Health expects will be diagnosed in more than 5,400 people this year. The drug is intended for patients whose disease has progressed after treatment with at least two drugs of a class used to treat the disease.

 BASEL, Switzerland — Progress at re-opening its manufacturing facility in Lincoln, Neb., has been slow-going, Novartis reported Thursday, but the company has contracted third-party manufacturers to resume production of Excedrin, Lamisil and Triaminic. First shipments to retailers were made in October.